المؤلفون: O. V. Stanevich (11870051), D. S. Fomina (11870054), I. G. Bakulin (11870057), S. I. Galeev (11870060), E. A. Bakin (11870063), V. A. Belash (11870066), A. N. Kulikov (11870069), A. A. Lebedeva (11870072), D. A. Lioznov (11870075), Yu. S. Polushin (11870078), I. V. Shlyk (11870081), E. A. Vorobyev (11870084), S. V. Vorobyeva (11870087), T. V. Surovceva (11870090), N. V. Bakulina (11870093), M. A. Lysenko (11870096), I. S. Moiseev (11870099)

مصطلحات موضوعية: Medicine, Genetics, Immunology, Cancer, Science Policy, Infectious Diseases, Computational Biology, COVID-19, SARS-CoV-2, Ruxolitinib, Dexamethasone, Anti-cytokine therapy

Relation: https://figshare.com/articles/journal_contribution/Additional_file_1_of_Ruxolitinib_versus_dexamethasone_in_hospitalized_adults_with_COVID-19_multicenter_matched_cohort_study/17425895

الاتاحة: https://doi.org/10.6084/m9.figshare.17425895.v1